Replies to post #142452 on Biotech Values

[pcrutch]

It is important to understand the triple-neg patients basically respond to nothing after their first treatment. So seeing some responses in this very heavily treated population is definitely encouraging. That said, it's not like this is a huge breakthrough - this is not a miracle drug.

I agree. Not a miracle drug, but if given in the right population( and earlier in the disease), it would certainly be better than current options. This isnt some placebo controlled trial, so it gives their data more credence than most smallcaps. They're a smallcap, no way could they have run a 250+ Phase 2 trial and all of their other programs.